In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. Full HAELO trial results: https://nej.md/4gaSsbi
#EAACICongress2026
#EAACICongress2026
June 13, 2026 at 6:25 AM
In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. Full HAELO trial results: https://nej.md/4gaSsbi
#EAACICongress2026
#EAACICongress2026
#ACAAI25: A single 50-mg infusion of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (#HAE) appears to offer high rates of attack-free and long-term prophylaxis (#LTP)-free status.
Read here: https://bit.ly/3JCy3yg
#RareDisease #HereditaryAngioedema #LonvoZ #MedSky
Read here: https://bit.ly/3JCy3yg
#RareDisease #HereditaryAngioedema #LonvoZ #MedSky
One-Time Infusion of Lonvo-Z May Safely Prevent Attacks in HAE
Adverse events were common but were mostly mild to moderate reactions that resolved rapidly.
bit.ly
November 7, 2025 at 7:40 PM
#ACAAI25: A single 50-mg infusion of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (#HAE) appears to offer high rates of attack-free and long-term prophylaxis (#LTP)-free status.
Read here: https://bit.ly/3JCy3yg
#RareDisease #HereditaryAngioedema #LonvoZ #MedSky
Read here: https://bit.ly/3JCy3yg
#RareDisease #HereditaryAngioedema #LonvoZ #MedSky
Three therapies—#Berotralstat, #Sebetralstat, and #LonvoZ—could offer hope to those who suffer from #HAE attacks, which can be life-threatening.
Read the full feature here: https://bit.ly/3LJb9WX
#RareDisease #HereditaryAngioedema
Read the full feature here: https://bit.ly/3LJb9WX
#RareDisease #HereditaryAngioedema
New Treatment Approaches on the Horizon for Patients With HAE
Three therapies—berotralstat, sebetralstat, and lonvo-z—could offer hope to those who suffer from HAE attacks, which can be life-threatening.
bit.ly
January 20, 2026 at 6:56 PM
Three therapies—#Berotralstat, #Sebetralstat, and #LonvoZ—could offer hope to those who suffer from #HAE attacks, which can be life-threatening.
Read the full feature here: https://bit.ly/3LJb9WX
#RareDisease #HereditaryAngioedema
Read the full feature here: https://bit.ly/3LJb9WX
#RareDisease #HereditaryAngioedema
A single dose of #LonvoZ, @intelliatx.bsky.social #CRISPR therapy for #HAE, produced deep, long-lasting suppression of #Kallikrein and kept nearly all patients attack-free and off prophylaxis for months to years, with a strong safety profile.
Read here: https://bit.ly/48vZ5zN
#RareDisease #MedSky
Read here: https://bit.ly/48vZ5zN
#RareDisease #MedSky
Single-Dose CRISPR Therapy Shows Durable HAE Control
A single dose of lonvo-z kept nearly all patients with HAE attack-free and off prophylaxis for months to years.
bit.ly
December 2, 2025 at 6:33 PM
A single dose of #LonvoZ, @intelliatx.bsky.social #CRISPR therapy for #HAE, produced deep, long-lasting suppression of #Kallikrein and kept nearly all patients attack-free and off prophylaxis for months to years, with a strong safety profile.
Read here: https://bit.ly/48vZ5zN
#RareDisease #MedSky
Read here: https://bit.ly/48vZ5zN
#RareDisease #MedSky
A #one-#time #infusion of an in vivo #gene-#editing #treatment vs. placebo reduced the monthly rate of #hereditary #angioedema attacks in patients aged 16 years and older, according to results published in The New England Journal of Medicine.
www.healio.com/news/...
www.healio.com/news/...
June 26, 2026 at 12:11 PM
A #one-#time #infusion of an in vivo #gene-#editing #treatment vs. placebo reduced the monthly rate of #hereditary #angioedema attacks in patients aged 16 years and older, according to results published in The New England Journal of Medicine.
www.healio.com/news/...
www.healio.com/news/...